Projects

Research subject
Asian multicenter prospective study of circulating tumor DNA sequencing: A-TRAIN
Institution
National Cancer Center Hospital
Principal investigator
Kan Yonemori
Contact (email)
ncch1905_office@ml.res.ncc.go.jp
Study outline
To perform next-generation sequencing (NGS) of cell free-DNA (cfDNA) in blood samples from Asian cancer patients, and to analyze the types and incidences of genetic abnormalities in this population.
  • Area of the study
    Cancer
    Development items
    ---
    Regulatory approval
    Others
    Main country where studies are conducted
    Led by Japan
    Number of participating countries, Number of participating institutions
    Number of participating countries:9, Number of participating institutions:18
    Participating countries' names
    India, South Korea, Philippines, Malaysia, Thailand, Singapore, Taiwan, Vietnam, Japan
    Study design
    Observational study
    Development phase
    Others
    Sample size
    550
  • Website
    Registered(ClinicalTrials.gov Identifier: NCT05099978)
    Intellectual property
    Yes
    Preclinical study
    ---
    Sponsoring company
    Yes
    Planning of licensing-out
    Not planned
    Domestic funding
    Yes
    Funding abroad
    Yes in some of the countries(Pangetsu Family Grant, Singapore)
    Contract
    Completed in some of the countries
    Procurement of investigational product
    Completed in some of the countries
  • Steering Committee
    No
    Development roadmap
    Fixed
    Stage of the study
    In the process of patient registration
    Protocol
    Using a single protocol as a single study
    IRB application
    Completed in some of the countries
    Data management
    In Japan
    Monitoring
    None
    Consultation with regulatory authorities
    Not completed yet in any countries
Current issues & challenges
(request for support, etc.)
---

CONTACT

If you wish to collaborate on a listed project, or if you wish to propose a joint research project, please fill in the Contact Form and submit it.